J Am Dent Assoc. 2024 Apr;155(4):304-311. doi: 10.1016/j.adaj.2023.11.011. Epub 2024 Jan 20.
The authors evaluated the synergistic analgesic effect of preemptive administration of 400 mg of ibuprofen (IBU) and potassium fluoride 2% (KF2), both in isolation or combination, on the painful perception of tooth sensitivity after tooth bleaching.
Fifteen patients participated in this triple-blind, randomized, placebo-controlled clinical trial. The study used a crossover design for drug administration and a split-mouth design for desensitizer agent. Four paired groups were formed: IBU plus KF2 (IBU + KF2); IBU (IBU + placebo KF); KF2 (placebo IBU + KF2), and placebo (placebo IBU + placebo KF). The outcome measure was the perception of tooth sensitivity, assessed using a visual analog scale. Data were collected at 4 different times: immediately after tooth bleaching (baseline) and after 6, 30, and 54 hours. Statistical analysis was performed using the Friedman test and relative risk.
IBU plus KF2 was found to be more effective in reducing tooth sensitivity immediately after bleaching (baseline) compared with the placebo group (P < .05). The risk of experiencing moderate or severe tooth sensitivity was approximately 4 times higher in the placebo group than in the IBU plus KF2 group (relative risk, 4.00; 95% CI, 1.01 to 15.81; P = .025).
The combined use of 400 mg of IBU and KF2 appears to be beneficial in managing postbleaching tooth sensitivity. It provides a superior analgesic effect compared with placebo.
The preemptive administration of IBU plus KF2 reduces tooth sensitivity after tooth whitening when compared with placebo. This clinical trial was registered in the Brazilian Clinical Trials Registry Platform. The registration number is U1111-1249-8191.
作者评估了在牙齿漂白后,单独或联合使用 400 毫克布洛芬(IBU)和 2%氟化钾(KF2)的预先给药对牙齿敏感疼痛的协同镇痛效果。
15 名患者参与了这项三盲、随机、安慰剂对照的临床试验。该研究采用药物给药的交叉设计和脱敏剂的分口设计。形成了四个配对组:IBU+KF2(IBU+KF2);IBU(IBU+安慰剂 KF);KF2(安慰剂 IBU+KF2)和安慰剂(安慰剂 IBU+安慰剂 KF)。使用视觉模拟量表评估牙齿敏感感知作为主要观察指标。数据在 4 个不同时间点收集:牙齿漂白后立即(基线)和 6、30 和 54 小时后。使用 Friedman 检验和相对风险进行统计分析。
与安慰剂组相比,IBU+KF2 可更有效地降低牙齿漂白后立即(基线)的牙齿敏感性(P<.05)。与 IBU+KF2 组相比,安慰剂组发生中度或重度牙齿敏感的风险约高 4 倍(相对风险 4.00;95%CI,1.01 至 15.81;P=.025)。
联合使用 400 毫克 IBU 和 KF2 似乎有益于管理牙齿漂白后敏感性。与安慰剂相比,它提供了更好的镇痛效果。
与安慰剂相比,IBU+KF2 的预先给药可降低牙齿漂白后牙齿敏感。本临床试验在巴西临床试验注册平台上进行。注册号为 U1111-1249-8191。